Working… Menu
Trial record 1 of 1 for:    tab001-01
Previous Study | Return to List | Next Study

Safety, Tolerability and Pharmacokinetics of an Anti-PD-1 Monoclonal Antibody in Subjects With Advanced Malignancies

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT03474640
Recruitment Status : Recruiting
First Posted : March 22, 2018
Last Update Posted : April 27, 2021
TopAlliance Biosciences, Inc.
Iqvia Pty Ltd
Information provided by (Responsible Party):
Shanghai Junshi Bioscience Co., Ltd.

No Study Results Posted on for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : August 2022
Estimated Study Completion Date : August 2023